Aldeyra Therapeutics Stock News

Midway through trading Tuesday, the Dow traded up 1.15% to 35,332.22 while the NASDAQ rose 0.94% to 15,122.12. The SP also rose, gaining 0.80% to 4,605.08. The U.S. has the highest number of coronavirus cases

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients Show Lackluster Efficacy CytomX

Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease. The trial failed to meet the primary endpoint of

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra or the Company), a biotechnology company developing novel immune-modulating therapies to treat ocul

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) shares crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $8.24 and traded as low as $6.70. Aldeyra Therapeutics shares last traded at $7.01, with a volume of 797,943 shares. ALDX has been the subject of a number of research reports. []

Investors need to pay close attention to Aldeyra (ALDX) stock based on the movements in the options market lately.

Investors need to pay close attention to Aldeyra (ALDX) stock based on the movements in the options market lately.

In the last trading session, 1.09 million Aldeyra Therapeutics Inc. (NASDAQ:ALDX) shares changed hands as the companys beta touched 1.67. With the companys per share price at $7.33 changed hands at $0.44 or 6.39% during last session, the market valuation stood at $452.99M. ALDXs last price was a discount, traded about -117.6% off its 52-week Aldeyra Therapeutics Inc. (NASDAQ: ALDX): Time To Buy Over The Next Few Months Read More »

Price T Rowe Associates Inc. MD bought a new stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 11,264 shares of the biotechnology companys stock, valued at approximately $128,000. Several other institutional investors have also modified their []

Brokerages forecast that Aldeyra Therapeutics, Inc (NASDAQ:ALDX) will post earnings per share (EPS) of ($0.30) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Aldeyra Therapeutics earnings, with the lowest EPS estimate coming in at ($0.32) and the highest estimate coming in at ($0.27). Aldeyra Therapeutics posted earnings of ($0.35) []

In last trading session, Aldeyra Therapeutics Inc. (NASDAQ:ALDX) saw 1.08 million shares changing hands with its beta currently measuring 1.63. Companys recent per share price level of $7.38 trading at -$0.29 or -3.78% at ring of the bell on the day assigns it a market valuation of $441.10M. That closing price of ALDXs stock is Aldeyra Therapeutics Inc. (NASDAQ:ALDX) Climbs 50.70% In 2021; Is It Attractive Enough At $7.38? Read More »

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) was the recipient of unusually large options trading activity on Monday. Stock investors acquired 18,039 call options on the company. This represents an increase of approximately 1,205% compared to the typical volume of 1,382 call options. A number of hedge funds have recently added to or reduced their stakes in ALDX. […]

Virtu Financial LLC acquired a new stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 12,824 shares of the biotechnology companys stock, valued at approximately $145,000. Several other institutional investors have also recently added to []

Nuveen Asset Management LLC bought a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 348,125 shares of the biotechnology companys stock, valued at approximately $3,944,000. Nuveen Asset Management LLC owned approximately 0.60% []

JPMorgan Chase & Co. lifted its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 38,795.8% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,670 shares of the biotechnology companys stock after buying an additional 18,622 shares during the period. JPMorgan Chase & Co.s holdings []